



INFORMATION OF HIGHTIDE

Established in 2011, HighTide is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. HighTide has developed a product pipeline of one core product and other four product candidates in-house. Its core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

As at the date of this announcement, the Company is interested in approximately 24.06% of the total issued share capital of HighTide. It is expected that immediately upon completion of the Proposed Offering and Listing, the Company's interest in the share capital of HighTide, which will be adjusted according to the number of shares to be issued by HighTide. HighTide will remain an associate of the Company.

Shareholders and potential investors of the Company should be aware that the consummation of the Proposed Offering and Listing is subject to fulfilment of conditions precedent. There is no assurance that the Proposed Offering and Listing will take place as contemplated or at all. Accordingly, shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares or other securities of the Company.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
December 18, 2023

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.